Reuters: Regulatory News: Pfizer gets fresh cancer drug rejection from UK cost body

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Pfizer gets fresh cancer drug rejection from UK cost body Jul 15th 2013, 23:01 LONDON, July 16 | Mon Jul 15, 2013 7:01pm EDT LONDON, July 16 (Reuters) - Pfizer's new chronic myeloid leukaemia drug Bosulif - also known as bosutinib - is too expensive to be used by Britain's state health service, the country's cost agency NICE said on Tuesday. The latest draft guidance from the National Institute for Health and Clinical Excellence (NICE), which is subject consultation, follows two earlier rebuffs for new cancer drugs developed by Pfizer this year.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions